Atorvastatin potentiates the chemosensitivity of human liver cancer cells to cisplatin via downregulating YAP1
- Liwen Guo
- Jiaping Zheng
- Hui Zeng
- Zhewei Zhang
- Guoliang Shao
Affiliations: Department of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China
- Published online on: December 1, 2020 https://doi.org/10.3892/ol.2020.12343
Copyright: © Guo
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Atorvastatin is a competitive inhibitor of β‑hydroxy β‑methylglutaryl‑CoA reductase, which is involved in anticancer effects in numerous types of cancer, including in human liver cancer. However, its functions and underlying mechanisms of chemosensitivity in liver cancer remain to be elucidated. The present study investigated the effect of atorvastatin on cisplatin chemosensitivity and its molecular mechanisms, with a focus on the Yes1‑associated transcriptional regulator (YAP1) protein. The present study demonstrated that atorvastatin significantly potentiated chemosensitivity to cisplatin in the liver cancer HepG2 and Huh‑7 cell lines. Furthermore, cell survival and apoptosis in liver cancer cell lines were analyzed using MTT assay and flow cytometry, respectively. Atorvastatin suppressed HepG2 and Huh‑7 cell viability in a dose‑dependent manner, similar to cisplatin and paclitaxel. Subtoxic levels of atorvastatin significantly increased cisplatin‑induced apoptosis in Huh‑7 cells. Atorvastatin‑promoted chemosensitivity was predominantly mediated by caspase 3, caspase 9 and poly‑(ADP ribose)‑polymerase activation, and YAP1 downregulation. Finally, YAP1 overexpression significantly reversed the susceptibility of Huh‑7 cells to cisplatin. Overall, the results of the present study suggested the underlying mechanisms of atorvastatin chemosensitivity in inducing liver cancer cell apoptosis via downregulating YAP1 and implicated the potential application of atorvastatin‑potentiated chemosensitivity in liver cancer therapy.